Press release year list 2021 2020 2019 2018 2017 2016 2014 2013
Sep 22, 2021
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
Download PDFPDF format download (opens in new window)
Sep 21, 2021
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
Download PDFPDF format download (opens in new window)
Sep 16, 2021
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
Download PDFPDF format download (opens in new window)
Sep 15, 2021
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
Download PDFPDF format download (opens in new window)
Sep 13, 2021
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
Download PDFPDF format download (opens in new window)
Sep 10, 2021
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
Download PDFPDF format download (opens in new window)
Aug 12, 2021
AbCellera Reports Q2 2021 Business Results
Download PDFPDF format download (opens in new window)
Aug 04, 2021
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
Download PDFPDF format download (opens in new window)
Aug 03, 2021
Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer
Download PDFPDF format download (opens in new window)
Jul 22, 2021
AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021
Download PDFPDF format download (opens in new window)
Jul 13, 2021
AbCellera Appoints Neil Berkley as Chief Business Officer
Download PDFPDF format download (opens in new window)
Jun 22, 2021
AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada
Download PDFPDF format download (opens in new window)
Jun 10, 2021
AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares
Download PDFPDF format download (opens in new window)
May 13, 2021
AbCellera Reports Q1 2021 Business Results
Download PDFPDF format download (opens in new window)
May 11, 2021
AbCellera to Present Virtually at Berenberg Conference on May 18, 2021
Download PDFPDF format download (opens in new window)
May 06, 2021
AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy
Download PDFPDF format download (opens in new window)
May 04, 2021
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
Download PDFPDF format download (opens in new window)
Apr 29, 2021
AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals
Download PDFPDF format download (opens in new window)
Apr 21, 2021
AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021
Download PDFPDF format download (opens in new window)
Apr 14, 2021
AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration
Download PDFPDF format download (opens in new window)
Apr 12, 2021
AbCellera to Present Virtually at Upcoming Investor Conferences
Download PDFPDF format download (opens in new window)
Apr 05, 2021
Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19
Download PDFPDF format download (opens in new window)
Apr 01, 2021
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
Download PDFPDF format download (opens in new window)
Mar 29, 2021
AbCellera Reports Full Year 2020 Business Results
Download PDFPDF format download (opens in new window)
Mar 10, 2021
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
Download PDFPDF format download (opens in new window)
Mar 05, 2021
EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
Download PDFPDF format download (opens in new window)
Feb 17, 2021
AbCellera to Present at the SVB Leerink Global Healthcare Conference
Download PDFPDF format download (opens in new window)
Feb 11, 2021
AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer
Download PDFPDF format download (opens in new window)
Feb 09, 2021
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
Download PDFPDF format download (opens in new window)
Feb 03, 2021
AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call
Download PDFPDF format download (opens in new window)
Jan 27, 2021
AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19
Download PDFPDF format download (opens in new window)
Jan 26, 2021
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%
Download PDFPDF format download (opens in new window)
Jan 21, 2021
AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents
Download PDFPDF format download (opens in new window)
Jan 19, 2021
AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology
Download PDFPDF format download (opens in new window)
Jan 14, 2021
adMare Launches Abdera with AbCellera as a Founding Partner
Download PDFPDF format download (opens in new window)